Experimental cell treatment aims to calm MS Flare-Ups
NCT ID NCT04530318
Summary
This study is testing whether adding a special immune cell therapy (called TolDec) to standard MS medications can better control the disease. The therapy involves taking a patient's own cells, modifying them in a lab, and reinfusing them to help calm the overactive immune response that attacks the nervous system in MS. Researchers will track 45 adults with relapsing-remitting MS for 24 weeks to see if the combination reduces brain lesions and relapses compared to standard care alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Moisés Broggi
L'Hospitalet de Llobregat, Barcelona, Spain
-
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
-
Hospital de Sant Pau
Barcelona, Spain
-
Hospital del Mar
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.